What is Modavar Pharmaceuticals?
Modavar Pharmaceuticals operates as a vertically integrated specialty pharmaceutical entity, functioning as a key subsidiary of Cadila Pharmaceuticals. The firm specializes in the development, manufacturing, and commercialization of high-quality prescription products. By leveraging FDA-compliant facilities located in the United States and India, Modavar maintains a robust infrastructure that supports both its proprietary drug pipeline and comprehensive contract manufacturing services. The company's core mission centers on the discovery and delivery of affordable therapeutic solutions designed to address a wide spectrum of medical conditions, ranging from disease prevention to complex diagnostic and curative treatments.
How much funding has Modavar Pharmaceuticals raised?
Modavar Pharmaceuticals has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Modavar Pharmaceuticals
PPP
Public-Private Partnership
What's next for Modavar Pharmaceuticals?
Following this late-stage funding round, Modavar Pharmaceuticals is expected to prioritize the scaling of its manufacturing capacity and the advancement of its research and development initiatives. The strategic allocation of these funds will likely focus on optimizing supply chain efficiencies and enhancing the company's ability to meet the growing demand for contract manufacturing services. By strengthening its technical capabilities and maintaining rigorous regulatory standards, Modavar aims to solidify its role as a critical partner in the global pharmaceutical supply chain, ultimately driving long-term value for stakeholders and improving patient access to essential medications.
See full Modavar Pharmaceuticals company page
